Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kenvue Inc. Common Stock (KVUE) vs Zoetis Inc (ZTS) Price & Performance

Kenvue Inc. Common StockTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Kenvue Inc. Common Stock vs Zoetis Inc — how do they compare? Kenvue Inc. Common Stock trades at $17.7 (market cap $34.06B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Kenvue Inc. Common Stock and Zoetis Inc are close in size by market cap, and Kenvue Inc. Common Stock pays the higher dividend (4.74%). Which is the better fit depends on your goals.

KVUEZTS
Market Cap
$34.06B$30.20B
Volume
23,267,2286,175,327
Sector
Consumer StaplesHealth
52-Week High
$19.83$147.53
52-Week Low
$14.11$69.09
Enterprise Value
$41.56B$37.76B
Dividend Yield
4.74%2.9%
Typical Hold Time
—70 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kenvue Inc. Common Stock

No Aura AI signal available yet.

Zoetis Inc

Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.

The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kenvue Inc. Common Stock

Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.

Read more on KVUE →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →